| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Judith M Smit. Clinical implications of treating depressed older adults with SSRIs: possible risk of hyponatremia. Journal of gerontological nursing. vol 36. issue 4. 2010-10-18. PMID:20180497. |
however, depression is a treatable illness, especially with the newer class of antidepressant agents, the selective serotonin reuptake inhibitors (ssris). |
2010-10-18 |
2023-08-12 |
Not clear |
| Dirk Eyding, Monika Lelgemann, Ulrich Grouven, Martin Härter, Mandy Kromp, Thomas Kaiser, Michaela F Kerekes, Martin Gerken, Beate Wiesele. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ (Clinical research ed.). vol 341. 2010-10-18. PMID:20940209. |
reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. |
2010-10-18 |
2023-08-12 |
Not clear |
| A Halari. Comorbidity between depression and cardiovascular disease. International angiology : a journal of the International Union of Angiology. vol 28. issue 2. 2010-10-12. PMID:19367238. |
platelet activation and hypercoaguability have been demonstrated in depression and appear to normalize with selective serotonin reuptake inhibitor (ssri) treatment. |
2010-10-12 |
2023-08-12 |
Not clear |
| Ramin V Parsey, R Todd Ogden, Jeffrey M Miller, Adrienne Tin, Natalie Hesselgrave, Ellen Goldstein, Arthur Mikhno, Matthew Milak, Francesca Zanderigo, Gregory M Sullivan, Maria A Oquendo, J John Man. Higher serotonin 1A binding in a second major depression cohort: modeling and reference region considerations. Biological psychiatry. vol 68. issue 2. 2010-10-12. PMID:20497898. |
higher serotonin 1a binding in a second major depression cohort: modeling and reference region considerations. |
2010-10-12 |
2023-08-12 |
human |
| Esther Nederhof, Esther M C Bouma, Albertine J Oldehinkel, Johan Orme. Interaction between childhood adversity, brain-derived neurotrophic factor val/met and serotonin transporter promoter polymorphism on depression: the TRAILS study. Biological psychiatry. vol 68. issue 2. 2010-10-12. PMID:20553751. |
interaction between childhood adversity, brain-derived neurotrophic factor val/met and serotonin transporter promoter polymorphism on depression: the trails study. |
2010-10-12 |
2023-08-12 |
Not clear |
| Esther Nederhof, Esther M C Bouma, Albertine J Oldehinkel, Johan Orme. Interaction between childhood adversity, brain-derived neurotrophic factor val/met and serotonin transporter promoter polymorphism on depression: the TRAILS study. Biological psychiatry. vol 68. issue 2. 2010-10-12. PMID:20553751. |
the three-way interaction between the functional polymorphism in the serotonin transporter gene linked promoter region, the val66met polymorphism in the brain-derived neurotrophic factor gene, and childhood adversity in the prediction of depression in children, reported by kaufman and colleagues in 2006, has only been confirmed in adult samples. |
2010-10-12 |
2023-08-12 |
Not clear |
| U Guenther, H Wrigge, N Theuerkauf, M F Boettcher, G Wensing, J Zinserling, C Putensen, A Hoef. Repinotan, a selective 5-HT1A-R-agonist, antagonizes morphine-induced ventilatory depression in anesthetized rats. Anesthesia and analgesia. vol 111. issue 4. 2010-10-11. PMID:20802053. |
opioid-induced ventilatory depression was shown to be counteracted in anesthetized rats by serotonin(1a)-receptor (5-ht(1a)-r)-agonist 8-oh-dpat, which cannot be applied to humans. |
2010-10-11 |
2023-08-12 |
rat |
| Susannah E Murph. Using functional neuroimaging to investigate the mechanisms of action of selective serotonin reuptake inhibitors (SSRIs). Current pharmaceutical design. vol 16. issue 18. 2010-10-08. PMID:20370666. |
selective serotonin reuptake inhibitors (ssris) are effective in the treatment of depression and a range of anxiety disorders [1;2]. |
2010-10-08 |
2023-08-12 |
human |
| Alessandro Bartolomucci, Valeria Carola, Tiziana Pascucci, Stefano Puglisi-Allegra, Simona Cabib, Klaus-Peter Lesch, Stefano Parmigiani, Paola Palanza, Cornelius Gros. Increased vulnerability to psychosocial stress in heterozygous serotonin transporter knockout mice. Disease models & mechanisms. vol 3. issue 7-8. 2010-10-07. PMID:20371729. |
however, there is significant individual variability in vulnerability to environmental risk factors, and genetic variation is thought to play a major role in determining who will become ill. several studies have shown, for example, that individuals carrying the s (short) allele of the serotonin transporter (5-htt) gene-linked polymorphic region (5-httlpr) have an increased risk for major depression following exposure to stress in adulthood. |
2010-10-07 |
2023-08-12 |
mouse |
| Alessandro Bartolomucci, Valeria Carola, Tiziana Pascucci, Stefano Puglisi-Allegra, Simona Cabib, Klaus-Peter Lesch, Stefano Parmigiani, Paola Palanza, Cornelius Gros. Increased vulnerability to psychosocial stress in heterozygous serotonin transporter knockout mice. Disease models & mechanisms. vol 3. issue 7-8. 2010-10-07. PMID:20371729. |
heterozygous 5-htt knockout mice exposed to high stress also showed significantly lower levels of serotonin turnover than wild-type littermates, selectively in the frontal cortex, which is a structure that is known to control fear and avoidance responses, and that is implicated in susceptibility to depression. |
2010-10-07 |
2023-08-12 |
mouse |
| Gonenc Kocabay, Mustafa Yildiz, Nilufer Eksi Duran, Mehmet Ozka. Sinus arrest due to sertraline. Clinical cardiology. vol 33. issue 6. 2010-10-04. PMID:20552630. |
sertraline is a selective serotonin reuptake inhibitor with established safety for the treatment of depression. |
2010-10-04 |
2023-08-12 |
Not clear |
| Thomas I F H Cremers, Eliyahu Dremencov, Fokko J Bosker, Ben H C Westerin. Oxazepam and temazepam attenuate paroxetine-induced elevation of serotonin levels in guinea-pig hippocampus. The international journal of neuropsychopharmacology. vol 13. issue 6. 2010-09-29. PMID:20047712. |
selective serotonin (5-ht) reuptake inhibitors (ssris) are used as a first-line treatment in depression. |
2010-09-29 |
2023-08-12 |
Not clear |
| B M Ruf, Z Bhagwaga. The 5-HT1B receptor: a novel target for the pathophysiology of depression. Current drug targets. vol 10. issue 11. 2010-09-27. PMID:19702551. |
evidence implicating 5-ht(1b) receptors in the pathophysiology of depression comes from a number of converging lines of research. |
2010-09-27 |
2023-08-12 |
rat |
| B M Ruf, Z Bhagwaga. The 5-HT1B receptor: a novel target for the pathophysiology of depression. Current drug targets. vol 10. issue 11. 2010-09-27. PMID:19702551. |
5-ht(1b) receptor agonists administered alone or with antidepressants have been shown to be effective in preclinical models of depression. |
2010-09-27 |
2023-08-12 |
rat |
| B M Ruf, Z Bhagwaga. The 5-HT1B receptor: a novel target for the pathophysiology of depression. Current drug targets. vol 10. issue 11. 2010-09-27. PMID:19702551. |
p11 plays a central role in the modulation of 5-ht(1b) receptor function and is dysregulated in preclinical models of depression and postmortem mdd samples. |
2010-09-27 |
2023-08-12 |
rat |
| B M Ruf, Z Bhagwaga. The 5-HT1B receptor: a novel target for the pathophysiology of depression. Current drug targets. vol 10. issue 11. 2010-09-27. PMID:19702551. |
a review of the literature provides strong evidence that 5-ht(1b) receptors and related factors such as p11 are involved in the pathophysiology of depression. |
2010-09-27 |
2023-08-12 |
rat |
| B M Ruf, Z Bhagwaga. The 5-HT1B receptor: a novel target for the pathophysiology of depression. Current drug targets. vol 10. issue 11. 2010-09-27. PMID:19702551. |
the following explores possible factors which may render the 5-ht(1b) receptor dysfunctional, resulting in susceptibility to depression. |
2010-09-27 |
2023-08-12 |
rat |
| Thangaraj Devadoss, Dilip K Pandey, Radhakrishnan Mahesh, Shushil K Yada. Effect of acute and chronic treatment with QCF-3 (4-benzylpiperazin-1-yl) (quinoxalin-2-yl) methanone, a novel 5-HT(3) receptor antagonist, in animal models of depression. Pharmacological reports : PR. vol 62. issue 2. 2010-09-27. PMID:20508279. |
effect of acute and chronic treatment with qcf-3 (4-benzylpiperazin-1-yl) (quinoxalin-2-yl) methanone, a novel 5-ht(3) receptor antagonist, in animal models of depression. |
2010-09-27 |
2023-08-12 |
mouse |
| Thangaraj Devadoss, Dilip K Pandey, Radhakrishnan Mahesh, Shushil K Yada. Effect of acute and chronic treatment with QCF-3 (4-benzylpiperazin-1-yl) (quinoxalin-2-yl) methanone, a novel 5-HT(3) receptor antagonist, in animal models of depression. Pharmacological reports : PR. vol 62. issue 2. 2010-09-27. PMID:20508279. |
in the current study, (4-benzylpiperazin-1-yl) (quinoxalin-2-yl) methanone (qcf-3), a novel 5-ht(3) receptor antagonist, with an optimal log p (the logarithm of the ratio of the concentrations of the un-ionized solute in the solvents is called log p) and significant pa2 value (is a negative logarithm of the molar concentration of antagonist required to reduce the effect of multiple dose agonist to that of single dose) was screened for its anti-depressant potential using rodent behavioral models of depression. |
2010-09-27 |
2023-08-12 |
mouse |
| Samuel Estrada-Soto, Dalia González-Maldonado, Patricia Castillo-España, Francisco Aguirre-Crespo, Juan Carlos Sánchez-Salgad. Spasmolytic effect of Mentha pulegium L. involves ionic flux regulation in rat ileum strips. Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanshi. vol 46. issue 2. 2010-09-22. PMID:20551591. |
this extract (200 microg/ml) induced a significant depression on cumulative concentration-response curve for carbachol and serotonin (p<0.05). |
2010-09-22 |
2023-08-12 |
rat |